Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EirGenix Inc. (6589.TWO)
New Taipei City, TW
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.99% | -3.04% | -13.06% | -27.24% | -45.54% | -27.71% | -30.85% | -58.89% | -73.99% | +7.70% | +7.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-0.4% Q1'26: +69.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-9.6% Q1'26: +9.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-0.8% Q1'26: +152.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-80.3% Q1'26: -67.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-12.4% ★ Q1'26: -12.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-1.0% ★ Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.12× Q1'26: -2.06× (vs Q1'25)
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
476.09M
est: 477.00M (-0.2%)
|
1.07B
est: 1.07B (-0.2%)
|
1.70B
est: 1.68B (+1.2%)
|
1.48B
est: 1.52B (-2.4%)
|
1.02B
est: 919.00M (+11.3%)
|
1.01B
est: 895.00M (+12.7%)
|
1.01B
est: 1.25B (-19.7%)
|
1.28B
1.28B – 1.28B
+2.3% YoY
|
| EBITDA |
-728.75M
est: -157.79M (-361.9%)
|
-840.67M
est: -355.10M (-136.7%)
|
164.98M
est: -554.90M (+129.7%)
|
100.61M
est: -501.89M (+120.0%)
|
-664.41M
est: -303.99M (-118.6%)
|
-388.50M
est: -299.30M (-29.8%)
|
-806.59M
est: -418.35M (-92.8%)
|
-428.05M
-428.05M – -428.05M
-2.3% YoY
|
| EBIT |
-842.40M
est: -247.52M (-240.3%)
|
-1.01B
est: -557.06M (-81.8%)
|
-20.02M
est: -870.49M (+97.7%)
|
-104.68M
est: -787.33M (+86.7%)
|
-903.25M
est: -476.89M (-89.4%)
|
-690.08M
est: -438.93M (-57.2%)
|
-806.59M
est: -613.52M (-31.5%)
|
-627.74M
-627.74M – -627.74M
-2.3% YoY
|
| Net Income |
-860.93M
est: -1.48B (+41.8%)
|
-1.04B
est: -1.49B (+30.0%)
|
-42.58M
est: -58.17M (+26.8%)
|
-115.54M
est: 41.66M (-377.3%)
|
-915.21M
est: -502.06M (-82.3%)
|
-698.34M
est: -751.46M (+7.1%)
|
-760.55M
est: -360.58M (-110.9%)
|
-575.72M
-575.72M – -575.72M
-59.7% YoY
|
| SGA |
142.73M
est: 106.33M (+34.2%)
|
174.95M
est: 239.31M (-26.9%)
|
257.17M
est: 373.95M (-31.2%)
|
287.52M
est: 338.23M (-15.0%)
|
316.43M
est: 204.86M (+54.5%)
|
298.97M
est: 170.30M (+75.6%)
|
—
est: 238.04M (-100.0%)
|
243.55M
243.55M – 243.55M
+2.3% YoY
|
| EPS |
-5.39
est: -4.83 (-11.6%)
|
-5.15
est: -4.86 (-5.9%)
|
-0.18
est: -0.19 (+5.3%)
|
-0.38
est: 0.14 (-379.2%)
|
-3.00
est: -1.64 (-82.9%)
|
-2.29
est: -2.48 (+7.7%)
|
-2.51
est: -1.19 (-110.9%)
|
-1.90
-1.90 – -1.90
-59.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 873.6K | 0.06% |
| 2 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.01% | 19.7K | 0.56% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 279.1K | 0.39% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 61.7K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 27.3K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 3.04M | 0.06% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 216.0K | 0.28% |
| 8 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 106.0K | 0.29% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 55.5K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 3.34M | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lee-Cheng Liu | Founder, President, Chief Executive Officer, CSO & Chairman | 20M | — |
| Chih-Jung Chang | Senior Vice President, Chief Executive Officer, BMBU | 6M | — |
| Hsiu-Chuan Yang | Chief Financial Officer, Vice President & Manager of Corporate Governance | 5M | female |
| Ching-Ying Chen | Executive Director | 5M | female |
| Shang-Chung Ju | Executive Director & Chief Engineer | 4M | — |
| Xiuquan Yang | Accounting Supervisor | — | — |
| Ching-Wen Lin B.S | Senior Vice President & Chief Business Officer | — | — |
| Klaus Martin | Senior VP & CEO of Biopharmaceuticals Business Unit | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6589.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
